

Valneva COVID-19 candidate vaccine

Vaccine:

Vero cell based inactivated vaccine (VLA2001) with CpG1018 adjuvant from Dynavax. The virus has been inactivated with BPL, preserving the native structure of the S-protein. The same platform has also been used for a Japanese encephalitis vaccine approved by the FDA. The vaccine should be given in a 2 dose schedule.

Timeline:

Phase I start December 2020

Regulatory approval 2021

(10)(2a)

Dynavax will

provide adjuvant for 190 million doses of the vaccine.

The same adjuvant is also being used in the inactivated COVID-19 vaccine that is being developed by Sinovac.